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Abstract
Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-
epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel
nanobioconjugate based on a poly(b-L-malic acid) (PMLA) nanoplatform for TNBC treatment. The nanobioconjugate carries
anti-tumor nucleosome-specific monoclonal antibody (mAb) 2C5 to target breast cancer cells, anti-mouse transferrin
receptor (TfR) antibody for drug delivery through the host endothelial system, and Morpholino antisense oligonucleotide
(AON) to inhibit EGFR synthesis. The nanobioconjugates variants were: (1) P (BioPolymer) with AON, 2C5 and anti-TfR for
tumor endothelial and cancer cell targeting, and EGFR suppression (P/AON/2C5/TfR), and (2) P with AON and 2C5 (P/AON/
2C5). Controls included (3) P with 2C5 but without AON (P/2C5), (4) PBS, and (5) P with PEG and leucine ester (LOEt) for
endosomal escape (P/mPEG/LOEt). Drugs were injected intravenously to MDA-MB-468 TNBC bearing mice. Tissue
accumulation of injected nanobioconjugates labeled with Alexa Fluor 680 was examined by Xenogen IVIS 200 (live imaging)
and confocal microscopy of tissue sections. Levels of EGFR, phosphorylated and total Akt in tumor samples were detected
by western blotting. In vitro western blot showed that the leading nanobioconjugate P/AON/2C5/TfR inhibited EGFR
synthesis significantly better than naked AON. In vivo imaging revealed that 2C5 increased drug-tumor accumulation.
Significant tumor growth inhibition was observed in mice treated with the lead nanobioconjugate (1) [P=0.03 vs. controls;
P,0.05 vs. nanobioconjugate variant (2)]. Lead nanobioconjugate (1) also showed stronger inhibition of EGFR expression
and Akt phosphorylation than other treatments. Treatment of TNBC with the new nanobioconjugate results in tumor
growth arrest by inhibiting EGFR and its downstream signaling intermediate, phosphorylated Akt. The nanobioconjugate
represents a new generation of nanodrugs for treatment of TNBC.
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Introduction
Triple negative breast cancer (TNBC) is an aggressive breast
cancer phenotype characterized by lack of expression of estrogen
receptor (ER) and progesterone receptor (PR), as well as the
absence of overexpression of human epidermal growth factor
receptor-2 (HER-2) [1].
TNBC often presents as an advanced-stage disease and is treated
mostly by systemic administration of conventional chemotherapy
due to the lack of specific molecular markers expression [2].
Immunohistochemical analysis showed that TNBC is associated
with a high expression of proliferation marker Ki-67 as well as
several other markers favoring cancer cell growth, including
mutated p53, cyclin E, epidermal growth factor receptor-1 (HER-
1, EGFR), vimentin, P-cadherin, and mutated BRCA1.
Anti-EGFR therapy has been increasingly recognized as an
important treatment for breast cancer patients [3]. EGFR is a
member of the EGFR/ErbB/HER family of type I transmem-
brane tyrosine kinase receptors including ErbB1/HER-1 (EGFR),
ErbB2/HER-2/neu, ErbB3/HER-3, and ErbB4/HER-4 [4,5].
High expression of EGFR induces erroneous development and
unrestricted proliferation in a number of human malignancies,
including breast cancer [4]. Tumors overexpressing EGFR
represent clinically aggressive cases [6]. They tend to have more
rapid cell cycle progression, greater chemoresistance, inhibition of
apoptosis, increased angiogenesis, cell motility, and higher rates of
metastasis [7]. The clinical data indicated that EGFR expression
had a significant prognostic value in TNBC patients [8], with high
EGFR levels correlating with poor prognosis. Therefore, EGFR is
a potential therapeutic target for the successful treatment of
TNBC.
A variety of modalities for blocking EGFR expression and/or
function in cancer cells including anti-EGFR monoclonal
antibodies (mAbs) and EGFR tyrosine kinase inhibitors (TKI)
have been proven effective, particularly when used in combination
[4,5,7]. However, all of the conventional small molecule drugs are
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requiring high therapeutic concentrations, causing cardio- or
other toxicities as side effects. They are also characterized by lack
of tumor specificity. Increasingly, nano-based therapeutics have
been catching a great deal of attention for cancer treatment. For
instance, hyperthermia induced by gold nanoshells sensitized
radioresistant TNBC to radiation treatment [9].
The multifunctional polymeric delivery system demonstrated
significantly higher antitumor activity in primary and metastatic
cancers when compared with drug alone and a pegylated anti-
cancer agent [10].
Our aim is to develop an efficient drug delivery system to reach
the tumor site specifically, with the ability to carry multiple anti-
tumor therapeutic components simultaneously without harmful
effects on normal organs. A new nanobioconjugate was designed
and synthesized, which specifically delivered anti-EGFR Morpho-
lino antisense oligonucleotides (AON) into breast cancer cells and
efficiently inhibited tumor growth in vivo. The novel drug is based
on poly(b-L-malic acid) (PMLA) platform, which is non-toxic, non-
immunogenic, biodegradable, and is a tumor specific drug delivery
system with covalently conjugated anti-transferrin receptor (TfR)
mAb for transcytosis across the endothelial system [11,12]. The
drugs based on PMLA have been successfully used to treat HER-2
positive breast cancer and gliomas [13,14,15,16]. The nanobio-
conjugate can target specific cell and receptor types based on the
incorporation of mAbs into its structure [17]. PMLA can be
covalently conjugated to potential anticancer components such as
AONs while allowing them to retain their therapeutic activity
[14,18,19,20]. The targeting effect has been enhanced by tandem
conjugation of mAbs and anticancer components, making it a
novel platform with more efficiently targeted drug delivery
[16,21]. Multiple biomolecules can be attached to the platform
allowing the nanobioconjugate to block several molecular markers
at the same time to reduce tumor growth, angiogenesis, invasion,
and metastasis.
Morpholino AONs that specifically bind to mRNA and inhibit
protein synthesis are well established as one of the most powerful
specific tools for gene/protein inhibition. Preclinical studies of
AONs for cancer treatment showed promising results, and
Morpholinos are very stable in plasma making them good
candidates for systemic treatment [22,23,24]. AONs have been
used in vitro and in vivo and have showed significant inhibition of
various genes [24,25].
The nucleosome-specific mAb 2C5 has been of interest to
targeted drug therapy because of its binding specificity toward
tumor cells. This mAb is able to recognize and bind to a wide
variety of surface bound nucleosomes that are expressed on the
tumor cells of multiple cancer cell lines of multiple origins [26,27].
2C5 successfully enhanced the distribution of doxorubicin-loaded,
long-circulating, polyethylene glycol-coated liposomes (Doxil,
ALZA Corp.) in tumors in vivo [28].
The present nanobioconjugates were designed to target breast
cancer with 2C5 anti-tumor mAb and to inhibit the protein
synthesis of EGFR by specific AON. Additionally, a mAb to TfR
was attached to allow the nanoplatform to target the tumor
vasculature and pass through it. This unique combination of
features resulted in a highly specific drug, which accumulated in
the tumor tissue and inside tumor cells.
Results
1. Synthesis of Polymalic acid nanobioconjugates
The nanobioconjugates were synthesized for TNBC treatment
using the hierarchic organization as described previously, with
modifications [13]. Of the two sequences of AON specific for
EGFR (see materials), version 2 knocked down EGFR expression
better than version 1 (data not shown). Thus, we selected version 2
to be conjugated to the polymer platform. The absolute molecular
weight of the leading version of nanobioconjugate shown in Fig. 1
was 1,300 kDa determined by light scattering and close to the
calculated value based on design. Hydrodynamic diameters (nano
sizes) and f potentials of the nanobioconjugates in Fig. 1 are
summarized in Table 1. It has been reported that f potentials in
the range of 24.1 to 25.7 mV should be ideal to allow the
nanoparticles to attach to the cell membrane and for nanoparticle
internalization [29,30].
2. Various tumors express 2C5 antigen and transferrin
receptor
To investigate the expression level of 2C5 nucleosomal antigen
and TfR on different tumors, Western blot analysis was performed
to detect 2C5 antigen and TfR on breast cancer cell lines, MDA-
MB-468, MCF-7, and BT-474. High TfR expression was seen in
all cell lines tested. Although there was some fluctuation in the
expression level of 2C5 antigen, it was detected in all cell lines
(Fig. 2a). The highest 2C5 antigen expression was seen in MDA-
MB-468.
3. Nanobioconjugate carrying both tumor targeting 2C5
mAb and EGFR AON (P AON/2C5) significantly inhibits
EGFR expression on EGFR positive breast cancer cells in
vitro as compared to naked EGFR AON
To evaluate the suppressive effect of nanobioconjugate on the
expression of EGFR in high (MDA-MB-468, EGFR+++) and
moderate (SKBR-3, EGFR++) EGFR-positive breast cancer cells,
western blot analysis was performed. Both EGFR-positive cell lines
were treated with PBS (control), AON transduction reagent
Endoporter (5 mM), two different concentrations of EGFR AON
(5 mMo r1 0mM) with Endoporter, or three different concentra-
tions of nanobioconjugate (P /2C5 /AON) (1.25 mM, 2.5 mMo r
5 mM by AON). In both MDA-MB-468 and SKBR-3, the EGFR
expression was inhibited by high concentration of AON in
comparison with the Endoporter control.
P/AON/2C5 also efficiently inhibited EGFR expression in
both breast cancer cell lines. Interestingly, low concentrations
(1.25 mM for SKBR-3 and 2.5 mM for MDA-MB-468) of
nanobioconjugate were sufficient enough to markedly inhibit
EGFR expression. Furthermore, 5 mM of nanobioconjugate was
more effective than 10 mM of naked AON (Fig. 2b).
4. P/2C5 specifically accumulates in the tumor area
The mAb 2C5 has nucleosome-restricted specificity and is able
to recognize human tumor cells. 2C5 also works as a specific
ligand for liposome targeting to cells in vitro and in vivo [31]. To
confirm its tumor targeting property and successful conjugation of
the drug, imaging analysis was performed using the MDA-MB-468
subcutaneous tumor model. The fluorescent signal intensities in
the tumor and normal organs were measured and tumor/
reference intensity ratios were calculated as described previously
[15,21]. The imaging studies showed that the nanobioconjugate
with anti-tumor 2C5 attached to PMLA showed specific drug
delivery into implanted human breast tumors. Twenty-four hours
after the intravenous injection of drug, it accumulated mostly in
the tumor and draining organs, kidney and liver (Fig. 3a). Little
drug accumulation was seen in any organs other than the draining
organs (Fig. 3b).
Nanodrug to Treat Triple Negative Breast Cancer
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Nanobioconjugates Size in nm (SD) Polydispersity index (SD) Zeta potential in mV
PMLA 6.660.1 0.160.01 222.9











Figure 1. Nanobioconjugate schematic. The new version of nanobioconjugate was designed to inhibit EGFR expression by Morpholino AON in
vitro and in vivo. The components are Morpholino AON to EGFR (1) conjugated to the scaffold by disulfide bonds that are cleaved by glutathione in
the cytoplasm to release the free AONs; targeting antibodies 2C5 and TfR either alone or as a combination of mAbs to tumor cells (2a), mouse TfR (2b)
for tumor endothelial and cancer cell targeting, and receptor-mediated endocytosis; PEG for drug protection (3); L-leucine ethyl ester together with
polymer-COOH (4) for endosomal escape of the drug, and optional fluorescent reporter dye (fluorescein or Alexa Fluor 680) for imaging (5).
doi:10.1371/journal.pone.0031070.g001
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MDA-MB-468 breast cancer animal model
To confirm the tumor specificity of 2C5 mAb covalently
attached to the nanoplatform, the Alexa Fluor 680-labeled
nanobioconjugates (control P/IgG, P/2C5) or P/2C5/TfR were
injected through the tail vein of mice and images were taken
24 hours after the drug injection. Control polymer with IgG
showed only weak signal in the tumor (Fig. 4a). In contrast, P/2C5
showed higher accumulation in the tumor area in comparison
with P/IgG. Finally, P/2C5/TfR showed significantly enhanced
accumulation in the tumor in comparison to the other two groups
as determined in three independent experiments (Fig. 4a).
Subsequent confocal microscopy was performed on sections of
tumors removed 24 hours after intravenous injection of Alexa
Fluor 680-labeled drugs. Again, higher drug accumulation was
observed inside cancer cells in the case of P/2C5 as compared with
control. The highest drug accumulation was seen in the P/2C5/
TfR injected group (Fig. 4b).
6. The lead drug significantly suppresses EGFR-positive
triple negative breast tumor growth in vivo
We investigated the therapeutic effect of the nanobioconjugate
upon intravenous treatment using subcutaneous mouse models of
human breast tumor xenografts. We used the MDA-MB-468 cell
line that overexpresses EGFR for in vivo treatment experiments.
MDA-MB-468 tumor-bearing mice were treated with either PBS
(control), P (polymer alone, control), P/2C5, P/AON/2C5, or P/
AON/2C5/TfR. No body weight loss, morbidity, or death was
observed, indicating that all treatments were well tolerated (data
not shown).
There was no anti-tumor effect in the PBS-, P-, or P/2C5-
treated mice. Mice treated with P/AON/2C5 showed significant
Figure 2. Expression levels of 2C5 and EGFR (after treatment). (2a) Expression level of 2C5 antigen and transferrin receptor in breast cancer
cells. 2C5 antigen and TfR expression was studied by western blot analysis. All cell lines expressed TfR and 2C5 antigen. Consistent expression of TfR
was seen in all cell lines. 2C5 antigen was also expressed by all cell lines, with the highest expression in MDA-MB-231 (not shown). b-Actin was an
internal control to normalize gel loading. (2b) Inhibition of EGFR expression in vitro by P/AON/2C5. EGFR overexpressing breast cancer cells MDA-MB-
468 (TNBC) and SKBR-3 were treated with either PBS (control), Endoporter (5 mM), two different concentrations of EGFR AON (5 mMo r1 0mM) with
Endoporter, or three different concentrations of nanobioconjugate (P/AON/2C5) (1.25 mM, 2.5 mMo r5mM). Two different sequences of EGFR AONs
were used for this study (shown in Materials and Methods, 1. Reagents section). Since EGFR AON version 2 inhibited EGFR expression better than
version 1 in vitro, version 2 (shown here) was chosen for the entire study. 72 hour after treatment, total cell protein was harvested and subjected to
Western blot analysis as described in Materials and Methods. Decreased EGFR expression was observed in AON, or P/AON/2C5-treated tumor cells but
not in PBS or Endoporter-treated cells. In both cell lines, 10 mM of AON was required to inhibit EGFR. On the other hand, low concentrations (1.25 mM
for SKBR-3 and 2.5 mM for MDA-MB-468) of the nanobioconjugate significantly inhibited EGFR expression. GAPDH was an internal control to
normalize gel loading.
doi:10.1371/journal.pone.0031070.g002
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mouse was administered with P/2C5 intravenously. 24 hours later, the animal showed drug distribution mostly in the tumor, as well as in kidney and
liver (drug clearing organs). (3b), Other than in kidney and liver, the drug was seen exclusively in the tumor.
doi:10.1371/journal.pone.0031070.g003
Figure 4. Tumor-specific active targeting effect of the 2C5 antibody in vivo. MDA-MB-468 subcutaneous tumor-bearing mice were injected
with Alexa Fluor 680-labeled nanobioconjugates (P/IgG, control; P/2C5 or P/2C5/TfR) through their tail vein. The images were taken 24 hours after the
drug injection using Xenogen IVIS 200 system. Although the P/IgG barely accumulated in the tumor by EPR effect, the P/2C5 accumulated in the
tumor area significantly more than control (Fig. 4a and 4b, **p=0.001). The highest drug accumulation was seen in P/2C5/TfR treated group where
two different tumor targeting antibodies were combined (Fig. 4a and 4b: p=0.002 vs P/2C5; ***p=0.0001 vs P/IgG). Confocal microscopy confirmed
drug delivery efficiency of the nanopolymer with dual targeting antibodies, P/2C5/TfR (Fig. 4c).
doi:10.1371/journal.pone.0031070.g004
Nanodrug to Treat Triple Negative Breast Cancer
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The most profound anti-tumor effect was observed when mice
were treated with the lead drug with two targeting antibodies, P/
AON/2C5/TfR (Fig. 5a). The leading drug showed the highest
degree of inhibition of tumor growth within all treatment groups
with an enhanced tumor inhibitory effect compared to single-
antibody treatments (Fig. 5a; P,0.05 vs. P/AON/2C5; P,0.03
vs. all other treatment groups). Moreover, the tumor growth
inhibition seen in mice treated with either P/AON/2C5 or P/
AON/2C5/TfR within the first four days after the initial
treatment is noteworthy.
Hematoxylin and eosin staining (Fig. 5c) showed decreased
numbers of viable cells in P/AON/2C5 treated tumors.
Furthermore, there was significant necrotic change in the case of
P/AON/2C5/TfR treated tumors.
Western blot analysis using lysates of subcutaneous MDA-MB-
468 breast tumors after different treatments was performed to
evaluate whether the nanobioconjugate with AON inhibits EGFR
expression and its related signal. Tumor EGFR expression was
indeed inhibited by P/AON/2C5 (Fig. 5b). P/AON/2C5/TfR,
where two mAbs were combined, caused the highest inhibition of
EGFR expression in the tumor. Phosphorylated Akt, which is one
of the main downstream molecules in the EGFR-regulated
signaling pathway, was also reduced by the nanobioconjugates.
The version of nanobioconjugate with two antibodies (the lead
drug) showed the most dramatic decrease in the expression of p-
Akt signal (Fig. 5b), which supports the idea that the lead drug
inhibited breast cancer growth by blocking the EGFR-regulated
pathway. Total Akt expression was not changed by any treatment.
Discussion
We have previously shown that our nanobioconjugate drug
delivery system with PMLA as a platform specifically targeted
cancer cells and inhibited brain tumor growth and angiogenesis
[32,33]. A specific nanobioconjugate variant also significantly
inhibited HER-2 positive breast cancer growth both in vitro and in
vivo [16]. In this study, we investigated the therapeutic effects of the
nanobioconjugate carrying a combination of EGFR AON and
2C5 anti-tumor mAb along with TfR as active targeting for
EGFR-positive triple negative breast cancer treatment.
Breast cancer is the most common malignancy of women in the
U.S. and is the second leading cause of cancer mortality [34,35].
Unlike patients with ER/PR-positive or HER-2-overexpressing
Figure 5. Tumor inhibition in mouse model, and effects on EGFR expression and Akt phosphorylation. (5a) Tumor growth inhibition in
mice. MDA-MB-468 subcutaneous breast tumors treated systemically with P/AON/2C5, or P/AON/2C5/TfR were significantly inhibited compared with
PBS (control), P(polymer only), or P/2C5 (without anti-tumor component) (P,0.03). The highest inhibition of tumor growth was observed in mice
treated with P/AON/2C5/TfR (p,0.03 vs. controls; p,0.05 vs. P/AON/2C5). Error bars denote SEM. (5b) Expression of EGFR and phosphorylated Akt (p-
Akt) after treatment of EGFR-positive tumors in vivo. Western blot analysis showed the decrease in EGFR and p-Akt expression in P/AON/2C5-, or P/
AON/2C5/TfR -treated mice compared to controls. The highest inhibition of EGFR and p-Akt was seen upon treatment with P/AON/2C5/TfR where 2
targeting antibodies were combined. GAPDH was an internal control to normalize gel loading. (5c) Histopathological analysis of tumors. Hematoxylin
and eosin staining of tumors treated with PBS, P, P/2C5, P/AON/2C5 or the leading drug P/AON/2C5/TfR. Consistent with tumor size reduction data,
the leading drug P/AON/2C5/TfR treated tumor showed significant reduction in the number of viable tumor cells as compared to other treatments.
doi:10.1371/journal.pone.0031070.g005
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are limited due to the lack of a molecular target [1]. Recently, a
number of targeted agents have been considered for TNBC
including poly(ADP-ribose) polymerase (PARP) inhibitor, mTOR
(mammalian target of rapamycin) inhibitor, anti-VEGF mAb, and
anti-EGFR mAb [3].
EGFR activates downstream signaling pathways, such as the
phosphoinositide-3 kinase (PI3K)/Akt pathway, which mediates
cell proliferation, survival, and migration [36,37]. Anti-EGFR
therapy has been increasingly recognized as a potential treatment
for breast cancer patients, and recently, advances in this direction
have been made [5,38]. Furthermore, EGFR is an independent
prognostic factor for patients with TNBC [8]. Therefore, EGFR-
targeted therapy is one of the promising strategies for TNBC
treatment and can potentially improve therapeutic outcome in
TNBC patients.
Several novel EGFR inhibitors are currently in pre-clinical and
clinical development including mAbs and small-molecule tyrosine
kinase inhibitors. Gefitinib (Iressa
TM,A s t r a Z e n e c a )i sas m a l l -
molecule tyrosine kinase inhibitor of EGFR that binds reversibly
to the ATP-binding site of EGFR. However, phase II trials of
Gefitinib in refractory metastatic breast cancer yielded disap-
pointing responses [39]. Cetuximab (Erbitux
TM,I m C l o n e
Systems Incorporated) is a mAb that binds with high affinity to
the extracellular domain of EGFR, competes for ligand binding
and blocks activation of the receptor by EGF or TGF-a. It also
induces antibody-mediated receptor dimerization resulting in
receptor downregulation [38,40]. However, the phase I trial of
Cetuximab in combination with Paclitaxel against advanced
breast cancer was not considered promising [41]. Recently, the
dual kinase inhibitor, Lapatinib, which possesses tyrosine kinase
receptor inhibitory activity against both EGFR and HER-2,
appeared to improve the current model of tyrosine kinase
inhibition and became a novel anti-EGFR therapy [42].
However, despite this progress in anti-EGFR based cancer
treatments, they lack of tumor-specific delivery, which should
result in inefficient anti-tumor activity. For therapeutic effect,
high doses are needed, which lead to serious toxicity. The
nanobioconjugates are ideal drug delivery tools with enhanced
specificity to the tumor and are capable of carrying multiple drug
combinations on a single platform. The drug delivery efficiency is
significantly improved when the nanopolymer is combined with
multiple components such as targeting antibodies against a tumor
marker by exploiting both passive targeting through EPR effect
and active targeting by mAbs [43,44,45].
The synthesis of the complete nanobioconjugate on polymalic
acid nanoplatform with covalently attached EGFR AON in
combination with 2C5 and TfR mAbs has been successfully
achieved (Fig. 1). AON is a stable and promising option for cancer
treatment [24,25]. AON blocked EGFR on glioma cells as good as
siRNA resulting in significant tumor growth inhibition in vivo and
in vitro [46]. As Table 1 shows, the size (smaller than 30 nm) of
these conjugates and their slightly negative f potential make them
ideal for the interaction with the cell membrane and intracellular
internalization. In addition, the homogeneities of each product
were reflected by their polydispersity index.
Western blot analysis showed that P/AON/2C5 significantly
inhibited the expression of EGFR in vitro (Fig. 2b). The low dose of
nanobioconjugate was more effective than the high dose of naked
AON. This result suggests that the nanobioconjugate is a very
efficient delivery vehicle in terms of drug uptake and efficacy.
More importantly, unlike commercially available transduction
agents, PMLA is non-toxic and non-immunogenic, which is ideal
for systemic treatment.
It has been shown that 2C5 specifically targets tumor cells, and
thus it increases anti-cancer effect and reduces side effects of the
treatment [27,28,31]. In accordance with previously published
data, the nanobioconjugate carrying 2C5 mAb specifically
recognized the tumor, which suggests that the activity of the
tumor targeting 2C5 antibody was not changed during chemical
synthesis. A new version of nanobioconjugate carrying tumor
targeting 2C5 mAb and EGFR AON, P/AON/2C5, significantly
inhibited breast tumor growth in vivo (Fig. 5). Breast tumor growth
was inhibited even more when the animals were treated with P/
AON/2C5/TfR where two targeting antibodies were combined
on one nanobiopolymer. Previously, we have proven that tandem
configuration of specific antibodies enhanced tumor targeting
[16,21]. Therefore, targeting tumor vascular endothelium by
mouse anti-TfR mAb in combination with anti-tumor 2C5 mAb
significantly enhanced tumor targeting effect of the nanobiocon-
jugate.
Western blot analysis using tumor samples proved that the
nanobioconjugate efficiently delivered the AONs via attached
targeting antibodies into the tumor cells and this explained the
significant treatment effect observed with novel nanobioconjugate
to inhibit the growth of TNBC. A plausible mechanism of action
of this nanobioconjugate appears to be the inhibition through
EGFR block of Akt phosphorylation, which is a downstream target
of EGFR. A similar blockage of Akt phosphorylation in breast
cancer was also observed after successful treatment of HER-2-
positive breast cancer-bearing mice using another nanobioconju-
gate that inhibits HER-2 synthesis and activity [12].
The results of this study suggest that tumor-targeted nanobio-
conjugate carrying EGFR AON with significant anti-tumor
activity against EGFR-positive TNBC may represent a new
generation of cancer therapeutics with a potential for efficacy
against triple negative breast cancers.
Materials and Methods
1. Reagents
Two versions of Morpholino
TM-39-NH2 antisense oligonucleo-
tides to EGFR were custom made by Gene Tools (Philomath,
OR):
Version 1: 59- GGTCGCATCGCTGCTCCCCGAAGAG-39,
Version 2: 59- TCGCTCCGGCTCTCCCGATCAATAC-39
Highly purified, endotoxin-free poly(b-L-malic acid), Mw
(weight-averaged)=100 kDa, polydispersity=1.1, was obtained
from the culture broth of Physarum polycephalum. Rat anti-mouse
TfR mAb R17217 (mTfR) was purchased from Southern Biotech
(Birmingham, AL). Cysteamine (2-mercaptoethyl-1-amine hydro-
chloride), N-hydroxysuccinimide, other reagents and solvents were
of highest available purity and purchased from Sigma-Aldrich (St.
Louis, MO).
Mouse autoimmune mAb 2C5 recognizing tumor cell surface-
bound nucleosomes released from neighboring apoptotic tumor
cells was a gift from Prof. V.P. Torchilin (Northeastern University,
Boston, MA).
2. Synthesis of polymalic acid nanobioconjugates
The nanobioconjugates contain five to six key components
(Fig. 1): PMLA as the backbone of delivery carrier, Morpholino
AON for the inhibition of EGFR protein synthesis, tumor
vasculature targeting anti-mouse TfR mAb, targeting anti-tumor
2C5 mAb, 40% leucine ethyl ester as an endosome escape unit to
achieve cytoplasmic AON delivery, and 5% PEG5000 to increase
stability in the bloodstream. The preconjugate containing 40%
leucine ethyl ester, 5% PEG5000 and 10% of cysteamine (%
Nanodrug to Treat Triple Negative Breast Cancer
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synthesized by the methods described previously [13]. The
antibodies attached to the preconjugate were qualitatively and
quantitatively assayedby size exclusionHPLC. ELISA with purified
TfR and 2C5 antigen was used to verify functional reactivity of
attached antibodies as described. Conjugates for imaging were
fluorescently labeled with Alexa FluorH 680 C2-maleimide
(Invitrogen, Carlsbad, CA) by forming thioether with sulfhydryl
groups. Conjugate without AONs and mAb was used as a control.
3. The nanobioconjugate characterization
Chemical and physical characterization of nanobioconjugate
was performed by various methods including L-malate dehydro-
genase assay, PEG colorimetric determination and protein
quantification, size and f potential, HPLC, and ELISA. HPLC
was performed on a Hitachi analytical Elite LaChrom HPLC-UV
system and size exclusion column BioSep-SEC-S 3000 column.
The nanobioconjugate variants were characterized with respect to
their size (hydrodynamic diameter) on the basis of noninvasive
back-scattering (NIBS) and f potential from electrophoretic
mobility based on the Helmholtz-Smoluchowski formula, using
electrophoresis M3-PALS [19]. Both measurements were per-
formed in a Zetasizer Nano System ZS90 (Malvern Instruments,
Malvern, UK). Data on molecular size and f potential from three
independent measurements represent mean 6 standard deviation.
4. Cell lines and culture conditions
Human breast cancer cell lines MDA-MB-468 (TNBC, EGFR
positive), SKBR-3 (EGFR-positive), BT-474 (EGFR-positive), and
MCF-7 (EGFR-negative) were obtained from American Type
Culture Collection (Manassas, VA). SKBR-3 was cultured in
McCoy’s 5A medium with 10% fetal bovine serum and antibiotics.
All other cell lines were cultured in DMEM with the same
supplements.
5. Nomenclature
The term ‘‘nanobioconjugate’’ denotes the drug delivery system
with PMLA as the nanoplatform and various functional groups
covalently attached to it, specifically the rat anti-mouse TfR mAbs, and
leucine ethylester (LOEt) as the endosomal escape unit. The newly
synthesized versions of nanobioconjugate to treat EGFR-positive
breast cancer contained a single anti-cancer drug (EGFR AON) with
either one mAb (2C5) or two mAbs (2C5 and TfR). All versions of
nanobioconjugates used in this study are shown in Fig. 1 and Table 1.
6. Western blotting
The protein samples were harvested from a variety of breast
cancer cells (shown in Fig. 2.) and the expression level of 2C5
antigen and TfR were detected by western blotting as described
previously [47]. MDA-MB-468 EGFR-positive TNBC cells and
EGFR-positive SKBR-3 breast cancer cells were treated with one
of the following: PBS (control), Endoporter (control, transduction
reagent), AON to EGFR with Endoporter, and P/AON/2C5.
Cell lysates were collected 72 hours after treatment. EGFR and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, to normal-
ize gel load) expression was analyzed by western blotting.
MDA-MB-468 TNBC subcutaneous breast tumor bearing mice
were treated with controls (PBS); P(Polymer control), P/2C5, P/
AON/2C5, and P/AON/2C5/TfR. Cell lysates were prepared
from excised breast tumor samples and analyzed by western
blotting to detect EGFR, total Akt, phosphorylated Akt (p-Akt),
and GAPDH (for equal gel loading). All of the antibodies used
were purchased from Cell Signaling Technology (Beverly, MA).
7. Tumor xenografts in nude mice
All experiments with animals were performed in accordance
with the protocols approved by the Cedars-Sinai Medical Center
Institutional Animal Care and Use Committee (IACUC). Athymic
mice were purchased from Taconic (Hudson, NY). A total of
1610
7 MDA-MB-468 cells suspended in 150 ml of Matrigel (BD
Biosciences, Bedford, MA) were injected into the right flanks of 35
mice (5 mice per group), and treatment was commenced when
tumors reached an average size of .120 mm
3 (21 days after
injection). Mice were divided into 5 treatment groups and
administered either sterile PBS (control), P (Polymer control), P/
2C5, P/AON/2C5, or P/AON/2C5/TfR through the tail vein
twice a week. Treatments were performed 8 times (for 4 weeks).
Tumor sizes were measured with calipers twice a week, and tumor
volumes were determined using the formula: (length6width
2)6
(p/6).
Four days after the last treatment, the animals were anesthetized
with 3% isoflurane-air mixture and sacrificed by cervical
dislocation. Tumor samples were stained with hematoxylin and
eosin for morphological observation.
The same subcutaneous tumor model was used for the imaging
study.
8. In vivo imaging study
To assess the organ localization of nanobioconjugates, 1610
7
MDA-MB-468 human breast cancer cells suspended in 150 mlo f
Matrigel were implanted into the right thigh of athymic mice
(CrTac:NCr-Foxn1nu Homozygous, Taconic) as described above.
When tumors grew up to 120 mm
3, 160 ml of Alexa Fluor 680-
labeled Polycefin variants were injected intravenously at the
concentration of 4 mM. PMLA with IgG, P/IgG, was used as a
control. For the assessment of drug distribution and localization in
nude mice, animals were studied in a Xenogen IVIS 200 imager
under isoflurane anesthesia at different time points (before drug
administration, 1 h, 3 h, 6 h, and 24 h after the injection of the
drug). Twenty-four hours after drug administration, mice were
euthanized. Intra-arterial PBS perfusion was done in order to wash
out the circulating drugs in blood vessels. The tumor and major
organs were harvested to detect the fluorescent signal. The
fluorescent signal intensities in the tumor and different organs
were analyzed by Xenogen Living ImageH software, Version 2.50
(WaveMetrix, USA).
9. Confocal microscopy
To assess the tissue localization of nanobioconjugates, tumor-
bearing mice were injected through the tail vein with either Alexa
Fluor 680-labeled P/IgG (control), Alexa Fluor 680-labeled P/
2C5, or Alexa Fluor 680-labeled P/2C5/TfR, as above. Twenty-
four hours after drug administration, mice were euthanized,
tumors were harvested, snap-frozen in liquid nitrogen, and
embedded in OCT compound for the fluorescent signal detection
on sections by confocal microscopy (TCS SP5 X microscope;
Leica Microsystems, Mannheim, Germany).
10. Statistical analysis
Student’s t-test (for two groups) and analysis of variance
(ANOVA, for three or more groups) were used to calculate
statistical significance of the experimental results. GraphPad
Prism4 program (GraphPad Software, San Diego, CA) was
utilized for all calculations. Data are presented as mean 6
standard error of mean (SEM). The significance level was set at
P,0.05.
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